title: The management of invasive transitional cell carcinoma of the bladder. Results of definitive and preoperative radiation therapy in 390 patients treated at the Prince of Wales Hospital, Sydney, Australia.
abstract: The treatment results for invasive transitional cell carcinoma (TCC) of the bladder were assessed in a series of 390 patients referred to the Department of Radiation Oncology at the Prince of Wales Hospital, Sydney, Australia, during the period 1977 to 1988. These patients were managed by one of two strategies: cystectomy (87 patients) and radiation therapy (303 patients). Actuarial survival rates (death from any cause) were determined and comparisons were made using log-rank tests and Cox regression analyses. The mean follow-up time was 7.6 years. Independent prognostic factors for shorter survival were: the presence of a ureteric obstruction (P less than 0.001), increasing clinical stage (P less than 0.001), increasing patient age (P = 0.003), and earlier year of presentation (P = 0.008). Comparison of the two strategies indicated no significant difference in overall survival after adjusting for imbalances in prognostic factors (P = 0.007 unadjusted; P = 0.29 adjusted). The slightly longer survival of 46 patients from 1983 onward who received primary systemic chemotherapy (compared with 149 patients not given chemotherapy) was not statistically significant (P = 0.12 unadjusted; P = 0.56 adjusted for prognostic factors). The 5-year actuarial rates of severe complications were 8.0% after cystectomy and 5.3% after radiation therapy. In 303 patients treated by definitive radiation therapy, the 5-year actuarial rate of freedom from bladder failure for all clinical tumor stages was 44% (Tx, 67%; T1, 45%; T2, 56%; T3, 39%; and T4, 39%). These results suggest that definitive radiation therapy is a viable alternative to radical cystectomy for patients with invasive TCC of the bladder.
authors.affiliation: Department of Radiation Oncology, Prince of Wales Hospital, Randwick, NSW, Australia.
authors.forename: H
authors.initials: H
authors.lastname: Mameghan
authors.forename: R J
authors.initials: RJ
authors.lastname: Fisher
authors.forename: W H
authors.initials: WH
authors.lastname: Watt
authors.forename: M J
authors.initials: MJ
authors.lastname: Meagher
authors.forename: I M
authors.initials: IM
authors.lastname: Rosen
authors.forename: J
authors.initials: J
authors.lastname: Mameghan
authors.forename: S
authors.initials: S
authors.lastname: Brook
authors.forename: A P
authors.initials: AP
authors.lastname: Tynan
authors.forename: E I
authors.initials: EI
authors.lastname: Korbel
authors.forename: R J
authors.initials: RJ
authors.lastname: Millard
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002295:Carcinoma, Transitional Cell / Q000401:mortality* / Q000532:radiotherapy / Q000601:surgery; D015653:Cystectomy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011832:Radiation Injuries; D011879:Radiotherapy Dosage; D016019:Survival Analysis; D001743:Urinary Bladder / Q000528:radiation effects; D001749:Urinary Bladder Neoplasms / Q000401:mortality* / Q000532:radiotherapy / Q000601:surgery